NASDAQ:TLGT - Teligent Stock Price, Price Target & More

$3.53 -0.06 (-1.67 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$3.53
Today's Range$3.45 - $3.67
52-Week Range$2.43 - $9.54
Volume442,061 shs
Average Volume659,970 shs
Market Capitalization$192.05 million
P/E Ratio-18.58
Dividend YieldN/A
Beta0.72

About Teligent (NASDAQ:TLGT)

Teligent logoTeligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract manufacturing and formulation services. Teligent, Inc. sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.

Receive TLGT News and Ratings via Email

Sign-up to receive the latest news and ratings for TLGT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TLGT
CUSIPN/A
Phone856-697-1441

Debt

Debt-to-Equity Ratio2.70%
Current Ratio2.68%
Quick Ratio2.01%

Price-To-Earnings

Trailing P/E Ratio-18.58
Forward P/E Ratio-117.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$67.25 million
Price / Sales2.81
Cash Flow$0.0710 per share
Price / Cash49.74
Book Value$0.84 per share
Price / Book4.20

Profitability

EPS (Most Recent Fiscal Year)($0.19)
Net Income$-15,190,000.00
Net Margins-18.42%
Return on Equity-14.55%
Return on Assets-4.00%

Miscellaneous

Employees183
Outstanding Shares53,500,000

How to Become a New Pot Stock Millionaire

Teligent (NASDAQ:TLGT) Frequently Asked Questions

What is Teligent's stock symbol?

Teligent trades on the NASDAQ under the ticker symbol "TLGT."

How were Teligent's earnings last quarter?

Teligent (NASDAQ:TLGT) posted its quarterly earnings results on Thursday, March, 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.05. The business earned $16.10 million during the quarter, compared to analyst estimates of $13.54 million. Teligent had a negative net margin of 18.42% and a negative return on equity of 14.55%. View Teligent's Earnings History.

What price target have analysts set for TLGT?

3 analysts have issued 12-month price targets for Teligent's stock. Their forecasts range from $4.00 to $9.00. On average, they expect Teligent's stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Teligent.

What are Wall Street analysts saying about Teligent stock?

Here are some recent quotes from research analysts about Teligent stock:
  • 1. According to Zacks Investment Research, "Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. " (3/13/2018)
  • 2. Canaccord Genuity analysts commented, "We’re confident that the company’s revised expectations are achievable and delays at the agency will resolve in short order. We continue to view Teligent as a uniquely positioned generic company poised for meaningful growth over the next several years. We maintain our BUY rating and $11 price target on TLGT shares. Light revenue due to lidocaine ointment and Zantac; lidocaine solution a surprising star in the report. Teligent’s 2Q/17 revenue was $18.4 mm compared to our $19mm estimate and $20.3 mm consensus. In our post-launch thoughts, we believed investors were expecting a light quarter and potential downward revision to 2H/17 expectations. Adjusted loss per share was ($0.01) compared to our EPS estimate of +$0.01 and consensus of +$0.02. Teligent saw incremental competition and double-digit price erosion on lidocaine ointment and a return of a competitor on Zantac injection coupled with lower-than-expected Zantac utilization rates due to recent inventory shortages that changed physician use patterns." (8/8/2017)

Are investors shorting Teligent?

Teligent saw a decline in short interest during the month of March. As of March 29th, there was short interest totalling 7,146,940 shares, a decline of 19.5% from the March 15th total of 8,880,150 shares. Based on an average trading volume of 1,415,995 shares, the short-interest ratio is presently 5.0 days. Currently, 16.5% of the shares of the company are short sold.

Who are some of Teligent's key competitors?

Who are Teligent's key executives?

Teligent's management team includes the folowing people:
  • Mr. Jason Grenfell-Gardner, Chief Exec. Officer, Pres and Director (Age 43)
  • Mr. Stephen Richardson, Chief Scientific Officer (Age 52)
  • Mr. Damian Finio, Chief Financial Officer (Age 48)
  • Ms. Nadya Lawrence, Sr. VP of Technical Services (Age 49)
  • Mr. Martin Wilson, Gen. Counsel

Has Teligent been receiving favorable news coverage?

News coverage about TLGT stock has trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Teligent earned a daily sentiment score of 0.18 on Accern's scale. They also assigned media headlines about the company an impact score of 46.79 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Teligent?

Shares of TLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teligent's stock price today?

One share of TLGT stock can currently be purchased for approximately $3.53.

How big of a company is Teligent?

Teligent has a market capitalization of $192.05 million and generates $67.25 million in revenue each year. The company earns $-15,190,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Teligent employs 183 workers across the globe.

How can I contact Teligent?

Teligent's mailing address is 105 LINCOLN AVENUE, BUENA NJ, 08310. The company can be reached via phone at 856-697-1441 or via email at [email protected]


MarketBeat Community Rating for Teligent (TLGT)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  265
MarketBeat's community ratings are surveys of what our community members think about Teligent and other stocks. Vote "Outperform" if you believe TLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Teligent (NASDAQ:TLGT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Teligent in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 98.30%. The high price target for TLGT is $9.00 and the low price target for TLGT is $4.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.332.332.332.67
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00$7.00$9.3333
Price Target Upside: 98.30% upside182.26% upside83.25% upside44.03% upside

Teligent (NASDAQ:TLGT) Consensus Price Target History

Price Target History for Teligent (NASDAQ:TLGT)

Teligent (NASDAQ:TLGT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2018Canaccord GenuitySet Price TargetHold$4.00HighView Rating Details
8/23/2017Roth CapitalSet Price TargetBuy$9.00LowView Rating Details
8/14/2017Deutsche BankLower Price TargetHold$9.00 -> $8.00LowView Rating Details
6/29/2016JMP SecuritiesInitiated CoverageHoldN/AView Rating Details
6/22/2016Raymond JamesInitiated CoverageStrong-Buy$11.00N/AView Rating Details
4/26/2016OppenheimerReiterated RatingHoldN/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Teligent (NASDAQ:TLGT) Earnings History and Estimates Chart

Earnings by Quarter for Teligent (NASDAQ:TLGT)

Teligent (NASDAQ:TLGT) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $0.14 EPS

Teligent (NASDAQ TLGT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018Q4 2017($0.13)($0.08)$13.54 million$16.10 millionViewN/AView Earnings Details
11/6/2017Q3 2017($0.01)($0.08)$19.12 million$13.65 millionViewN/AView Earnings Details
8/8/2017Q2 2017$0.02($0.02)$20.11 million$18.40 millionViewListenView Earnings Details
5/2/2017Q1 2017$0.02$0.05$21.03 million$19.89 millionViewN/AView Earnings Details
3/7/2017Q4 2016$0.01$17.97 million$17.90 millionViewListenView Earnings Details
10/27/2016Q3($0.0030)$0.01$16.90 million$16.20 millionViewListenView Earnings Details
7/28/2016Q2($0.02)$0.02$16.03 million$17.14 millionViewListenView Earnings Details
4/28/2016Q116($0.03)$0.02$14.33 million$15.70 millionViewN/AView Earnings Details
3/9/2016Q415($0.02)($0.02)$11.69 million$13.10 millionViewN/AView Earnings Details
10/22/2015Q3 2015($0.04)($0.02)$9.35 million$11.62 millionViewN/AView Earnings Details
7/23/2015Q2 2015($0.07)($0.05)$7.51 million$8.89 millionViewN/AView Earnings Details
3/2/2015Q4 2014$0.06$0.06$11.87 million$13.74 millionViewN/AView Earnings Details
7/24/2014Q2 2014($0.01)$6.61 million$6.48 millionViewN/AView Earnings Details
2/27/2014Q4 2013$0.01($0.01)$5.60 million$6.73 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.01)$3.82 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.01)$2.40 million$3.68 millionViewN/AView Earnings Details
3/5/2013Q4 2012($0.03)ViewN/AView Earnings Details
11/13/2012Q3 2012($0.02)ViewN/AView Earnings Details
8/13/2012Q2 2012($0.01)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.02)ViewN/AView Earnings Details
3/20/2012Q4 2011($0.01)ViewN/AView Earnings Details
11/21/2011Q3 2011($0.01)ViewN/AView Earnings Details
8/16/2011Q2 2011($0.02)ViewN/AView Earnings Details
4/1/2009Q4 2008($0.04)ViewN/AView Earnings Details
11/14/2008Q3 2008($0.04)ViewN/AView Earnings Details
8/13/2008Q2 2008($0.05)ViewN/AView Earnings Details
3/31/2008Q4 2007$0.02ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Teligent (NASDAQ:TLGT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Teligent (NASDAQ TLGT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 22.80%
Institutional Ownership Percentage: 68.24%
Insider Trading History for Teligent (NASDAQ:TLGT)
Insider Trading History for Teligent (NASDAQ:TLGT)

Teligent (NASDAQ TLGT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2017Carole Ben-MaimonDirectorBuy5,000$3.48$17,400.002,400View SEC Filing  
11/10/2017Steven H KoehlerDirectorBuy5,000$3.62$18,100.001,800View SEC Filing  
11/9/2017Stephen RichardsonInsiderBuy6,410$3.13$20,063.3014,744View SEC Filing  
11/8/2017Jenniffer CollinsCFOBuy7,000$3.04$21,280.0019,206View SEC Filing  
3/11/2016James C GaleDirectorBuy15,000$4.91$73,650.0039,624View SEC Filing  
3/11/2016Jason Grenfell-GardnerCEOBuy10,500$4.82$50,610.00250,207View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Teligent (NASDAQ TLGT) News Headlines

Source:
DateHeadline
Pre-Open Movers 04/18: (NBEV) (TLGT) (TXT) (EBAY) Higher; (AGLE) (CATB) (LRCX) (IBM) Lower (more...)Pre-Open Movers 04/18: (NBEV) (TLGT) (TXT) (EBAY) Higher; (AGLE) (CATB) (LRCX) (IBM) Lower (more...)
www.streetinsider.com - April 18 at 4:52 PM
$15.62 Million in Sales Expected for Teligent (TLGT) This Quarter$15.62 Million in Sales Expected for Teligent (TLGT) This Quarter
www.americanbankingnews.com - April 18 at 3:56 AM
FDA OKs Teligents generic clobetasol cream; shares up 20% after hoursFDA OKs Teligent's generic clobetasol cream; shares up 20% after hours
seekingalpha.com - April 17 at 5:03 PM
Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Cream USP, 0.05%Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Cream USP, 0.05%
finance.yahoo.com - April 17 at 5:03 PM
Teligent (TLGT) Expected to Post Earnings of -$0.03 Per ShareTeligent (TLGT) Expected to Post Earnings of -$0.03 Per Share
www.americanbankingnews.com - April 16 at 11:18 AM
Teligent (TLGT) Research Coverage Started at Canaccord GenuityTeligent (TLGT) Research Coverage Started at Canaccord Genuity
www.americanbankingnews.com - April 15 at 9:43 AM
Teligent (TLGT) Downgraded to "Strong Sell" at BidaskClubTeligent (TLGT) Downgraded to "Strong Sell" at BidaskClub
www.americanbankingnews.com - April 14 at 4:47 PM
Short Interest in Teligent (TLGT) Decreases By 19.5%Short Interest in Teligent (TLGT) Decreases By 19.5%
www.americanbankingnews.com - April 13 at 3:23 AM
Roth Capital Analysts Give Teligent (TLGT) a $9.00 Price TargetRoth Capital Analysts Give Teligent (TLGT) a $9.00 Price Target
www.americanbankingnews.com - April 11 at 12:43 AM
BRIEF-Teligent Files For Mixed Shelf Of Up To $50 MlnBRIEF-Teligent Files For Mixed Shelf Of Up To $50 Mln
www.reuters.com - April 7 at 9:47 AM
Teligent (TLGT) Reports FDA Approval of Ciclopirox Shampoo, 1%Teligent (TLGT) Reports FDA Approval of Ciclopirox Shampoo, 1%
www.streetinsider.com - April 7 at 9:47 AM
Teligent Inc (TLGT) Receives Consensus Recommendation of "Hold" from AnalystsTeligent Inc (TLGT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 7 at 1:29 AM
BRIEF-FDA Grants Teligent Approval Of Ciclopirox Shampoo, 1%BRIEF-FDA Grants Teligent Approval Of Ciclopirox Shampoo, 1%
www.reuters.com - April 6 at 4:49 PM
Teligent, Inc. Announces FDA Approval of Ciclopirox Shampoo, 1%Teligent, Inc. Announces FDA Approval of Ciclopirox Shampoo, 1%
finance.yahoo.com - April 6 at 4:49 PM
Canaccord Genuity Lowers Teligent (TLGT) to HoldCanaccord Genuity Lowers Teligent (TLGT) to Hold
www.americanbankingnews.com - April 1 at 4:16 PM
Teligent Inc (TLGT) Expected to Announce Quarterly Sales of $15.62 MillionTeligent Inc (TLGT) Expected to Announce Quarterly Sales of $15.62 Million
www.americanbankingnews.com - April 1 at 3:46 AM
-$0.03 Earnings Per Share Expected for Teligent Inc (TLGT) This Quarter-$0.03 Earnings Per Share Expected for Teligent Inc (TLGT) This Quarter
www.americanbankingnews.com - March 30 at 1:18 PM
Blog Exposure - FDA Approved Teligent’s Halobetasol Propionate Ointment, 0.05%Blog Exposure - FDA Approved Teligent’s Halobetasol Propionate Ointment, 0.05%
finance.yahoo.com - March 23 at 9:16 AM
Teligent, Inc. Announces FDA Approval of Halobetasol Propionate Ointment, 0.05%Teligent, Inc. Announces FDA Approval of Halobetasol Propionate Ointment, 0.05%
finance.yahoo.com - March 21 at 10:23 AM
Teligent (TLGT) Given a $4.00 Price Target at Canaccord GenuityTeligent (TLGT) Given a $4.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - March 16 at 6:42 PM
Edited Transcript of TLGT earnings conference call or presentation 15-Mar-18 8:30pm GMTEdited Transcript of TLGT earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 5:35 PM
Teligent, Inc. to Host Earnings CallTeligent, Inc. to Host Earnings Call
finance.yahoo.com - March 15 at 5:06 PM
Teligent, Inc. Announces Fourth Quarter and Year End 2017 ResultsTeligent, Inc. Announces Fourth Quarter and Year End 2017 Results
finance.yahoo.com - March 15 at 5:06 PM
Teligent (TLGT) Upgraded by Zacks Investment Research to "Hold"Teligent (TLGT) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 13 at 3:57 PM
Teligent Inc (TLGT) Given Average Rating of "Hold" by AnalystsTeligent Inc (TLGT) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 13 at 1:46 AM
Teligent, Inc. to Hold Conference Call for Fourth Quarter 2017 ResultsTeligent, Inc. to Hold Conference Call for Fourth Quarter 2017 Results
finance.yahoo.com - March 12 at 5:39 PM
Teligent, Inc. to Present at the Raymond James 39th Annual Institutional Investors Conference on Wednesday March 7, 2018Teligent, Inc. to Present at the Raymond James 39th Annual Institutional Investors Conference on Wednesday March 7, 2018
finance.yahoo.com - March 5 at 5:08 PM
Teligent Inc (TLGT) Shares Bought by Broadfin Capital LLCTeligent Inc (TLGT) Shares Bought by Broadfin Capital LLC
www.americanbankingnews.com - March 3 at 4:55 AM
Canaccord Genuity Trims Teligent (TLGT) Target Price to $3.50Canaccord Genuity Trims Teligent (TLGT) Target Price to $3.50
www.americanbankingnews.com - March 2 at 10:03 PM
$13.54 Million in Sales Expected for Teligent Inc (TLGT) This Quarter$13.54 Million in Sales Expected for Teligent Inc (TLGT) This Quarter
www.americanbankingnews.com - February 26 at 4:54 AM
Teligent, Inc. Announces FDA Approval of Betamethasone Dipropionate Lotion USP (Augmented), 0.05%Teligent, Inc. Announces FDA Approval of Betamethasone Dipropionate Lotion USP (Augmented), 0.05%
finance.yahoo.com - February 22 at 9:08 AM
Teligent Inc (TLGT) Receives Average Recommendation of "Hold" from AnalystsTeligent Inc (TLGT) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 16 at 1:36 AM
Investor Expectations to Drive Momentum within Amerco, Caesars Entertainment, Air Products and Chemicals, Consolidated Edison, Teligent, and Versartis — Discovering Underlying Factors of InfluenceInvestor Expectations to Drive Momentum within Amerco, Caesars Entertainment, Air Products and Chemicals, Consolidated Edison, Teligent, and Versartis — Discovering Underlying Factors of Influence
finance.yahoo.com - February 14 at 9:15 AM
Zacks: Analysts Expect Teligent Inc (TLGT) Will Announce Quarterly Sales of $13.54 MillionZacks: Analysts Expect Teligent Inc (TLGT) Will Announce Quarterly Sales of $13.54 Million
www.americanbankingnews.com - February 9 at 2:50 AM
Zacks: Analysts Expect Teligent Inc (TLGT) to Post -$0.11 Earnings Per ShareZacks: Analysts Expect Teligent Inc (TLGT) to Post -$0.11 Earnings Per Share
www.americanbankingnews.com - February 7 at 11:16 AM
Pernix Therapeutics (PTX) versus Teligent (TLGT) Head to Head ComparisonPernix Therapeutics (PTX) versus Teligent (TLGT) Head to Head Comparison
www.americanbankingnews.com - February 6 at 9:14 PM
Teligent (TLGT) Names Damian Finio as Chief Financial OfficerTeligent (TLGT) Names Damian Finio as Chief Financial Officer
www.streetinsider.com - January 27 at 9:39 AM
BRIEF-Teligent Appoints Damian Finio As Chief Financial OfficerBRIEF-Teligent Appoints Damian Finio As Chief Financial Officer
www.reuters.com - January 26 at 4:18 PM
Teligent, Inc. Announces the Appointment of Damian Finio as Chief Financial OfficerTeligent, Inc. Announces the Appointment of Damian Finio as Chief Financial Officer
finance.yahoo.com - January 26 at 9:22 AM
Teligent Inc (TLGT) Receives Consensus Rating of "Hold" from AnalystsTeligent Inc (TLGT) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 22 at 1:40 AM
Contrasting Teligent (TLGT) & Dr.Reddy's Laboratories (RDY)Contrasting Teligent (TLGT) & Dr.Reddy's Laboratories (RDY)
www.americanbankingnews.com - January 12 at 11:30 AM
 Analysts Expect Teligent, Inc. (TLGT) to Post -$0.11 Earnings Per Share Analysts Expect Teligent, Inc. (TLGT) to Post -$0.11 Earnings Per Share
www.americanbankingnews.com - January 4 at 5:28 PM
Critical Analysis: Teligent (TLGT) & Emergent Biosolutions (EBS)Critical Analysis: Teligent (TLGT) & Emergent Biosolutions (EBS)
www.americanbankingnews.com - January 2 at 5:28 AM
Teligent, Inc. (TLGT) Receives Average Recommendation of "Hold" from AnalystsTeligent, Inc. (TLGT) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 28 at 2:12 AM
ETFs with exposure to Teligent, Inc. : December 27, 2017ETFs with exposure to Teligent, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 12:59 PM
$13.54 Million in Sales Expected for Teligent, Inc. (TLGT) This Quarter$13.54 Million in Sales Expected for Teligent, Inc. (TLGT) This Quarter
www.americanbankingnews.com - December 21 at 7:58 PM
Teligent, Inc. (TLGT) Expected to Announce Earnings of -$0.11 Per ShareTeligent, Inc. (TLGT) Expected to Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - December 19 at 3:12 AM
Analyzing Teligent (TLGT) & Celgene (CELG)Analyzing Teligent (TLGT) & Celgene (CELG)
www.americanbankingnews.com - December 17 at 5:32 AM
Teva to lay off 14,000 workers in bid for survival — but some are skepticalTeva to lay off 14,000 workers in bid for survival — but some are skeptical
finance.yahoo.com - December 14 at 11:31 AM
Teligent (TLGT) PT Set at $4.00 by Canaccord GenuityTeligent (TLGT) PT Set at $4.00 by Canaccord Genuity
www.americanbankingnews.com - December 10 at 7:16 AM

SEC Filings

Teligent (NASDAQ:TLGT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Teligent (NASDAQ:TLGT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Teligent (NASDAQ TLGT) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.